1414 ET - Life sciences and diagnostic tools companies are primed for surprisingly good 1Qs amid positive pre-announcements from Pacific Biosciences of California, Qiagen NV and Bruker, but don't fall for the initial positive news, Bank of America analysts say in a research note. "We wouldn't overreact to these initial prints," the analysts say, adding headwinds from National Institutes of Health budget cuts, tariffs and a trade war with China only materialized recently, giving companies one to two months of regular business activity in the 1Q. The real risk, then, lies in 2Q/3Q and the rest of FY25, the analysts say. They expect softer commentary particularly from academic and government exposed companies like Illumina, 10x Genomics and others, while diagnostics companies are likely a safer bet, they say. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
April 14, 2025 14:14 ET (18:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.